Copyright
©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Table 5 Patterns of recurrence and immune maintenance therapy
| Patterns of recurrence | Immune maintenance therapy | ||
| Local | Distant organ | ||
| Group A (20) | 4 (20%) | 1 (5%) | 10 (50%) |
| Group B (21) | 2 (9%) | 5 (24%) | 3 (14.3%) |
| Group C (14) | 2 (14.3%) | 4 (28.6%) | 7 (50%) |
- Citation: Wang HC, Huang X, Chen J, Li Y, Cong Y, Qu BL, Feng SQ, Liu F. Long-term efficacy and predictors of pembrolizumab-based regimens in patients with advanced esophageal cancer in the real world. World J Gastroenterol 2023; 29(41): 5641-5656
- URL: https://www.wjgnet.com/1007-9327/full/v29/i41/5641.htm
- DOI: https://dx.doi.org/10.3748/wjg.v29.i41.5641